Lexeo Therapeutics, Inc.’s (NASDAQ:LXEO) Lock-Up Period Set To End Tomorrow

Lexeo Therapeutics’ (NASDAQ:LXEO) lock-up period will end on Wednesday, May 1st. Lexeo Therapeutics had issued 9,090,910 shares in its initial public offering on November 3rd. The total size of the offering was $100,000,010 based on an initial share price of $11.00. After the expiration of Lexeo Therapeutics’ lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Lexeo Therapeutics Price Performance

Shares of LXEO opened at $12.30 on Tuesday. Lexeo Therapeutics has a twelve month low of $9.00 and a twelve month high of $22.33. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average price of $14.24.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its earnings results on Monday, March 11th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.15). On average, research analysts expect that Lexeo Therapeutics will post -3.04 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in LXEO. Blackstone Inc. bought a new position in shares of Lexeo Therapeutics in the fourth quarter worth about $9,342,000. Omega Fund Management LLC bought a new position in Lexeo Therapeutics during the 4th quarter worth about $28,955,000. Eventide Asset Management LLC bought a new position in Lexeo Therapeutics during the 4th quarter worth about $40,298,000. Finally, Cornell University bought a new position in Lexeo Therapeutics during the 1st quarter worth about $1,980,000. 60.67% of the stock is currently owned by institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.